Protagonist Therapeutics (PTGX) Price & Analysis

Compare

713 Followers

PTGX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$33.31 - $68.26

Previous CloseN/A

Volume120.35K

Average Volume (3M)1.07M

Market Cap

$4.06B

Enterprise Value$2.95B

Total Cash (Recent Filing)$570.47M

Total Debt (Recent Filing)$11.28M

Price to Earnings (P/E)94.1

Beta0.77

Next Earnings

Nov 05, 2025

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding62,211,320

10 Day Avg. Volume1,047,291

30 Day Avg. Volume1,071,819

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue14.49

Enterprise Value/Gross Profit14.54

Enterprise Value/Ebitda116.19

Forecast

1Y Price Target

$73.09

Price Target Upside-15.99% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Acquisition PotentialJNJ's acquisition interest in PTGX is likely due to PTGX's orally available peptide technology platform, which supports the development of additional promising candidates.

Clinical DevelopmentJNJ sees strong potential in PTGX's IL-17 and obesity programs, with promising preclinical data suggesting high efficacy.

Financial StabilityPTGX has a strong balance sheet, ending with total cash of $673.0M and a financial runway through at least YE28.

Bears Say

Market CompetitionIcotrokinra's IL23-targeting MOA, strong safety, and once daily oral convenience are seen as differentiating characteristics in IBD.

Regulatory UncertaintyDurable clinical remission could be a more important factor than safety, so data from the Ph3 studies should help to establish icotrokinra's clinical profile.

Protagonist Therapeutics News

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Economic updates, earnings reports, analyst coverage, and more are among the biggest stock market stories on Friday. ...

2d ago

AMD

M&A News: Protagonist Therapeutics Stock (PTGX) is Star of the Show on JNJ Bid Talk

Shares in Protagonist Therapeutics ($PTGX) looked heroic today on a report that it could soon be bought by...

2d ago

JNJ

PTGX

Protagonist Therapeutics rises 34.1%

Protagonist Therapeutics (PTGX) is up 34.1%, or $22.87 to $89.91. Published first on TheFly – the ultimate source...

2d ago

PTGX

Midday Fly By: Trump threatens China tariffs, Kalshi valued at $5B

Stocks advanced in early trading as markets looked set to cap off a week of gains despite the...

2d ago

Protagonist Therapeutics resumes, up 28% after report of J&J takeover talks

11:30 EDT Protagonist Therapeutics (PTGX) resumes, up 28% after report of J&J takeover talks Published first on TheFly...

2d ago

JNJ

PTGX

Protagonist Therapeutics trading resumes

11:28 EDT Protagonist Therapeutics (PTGX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2d ago

PTGX

J&J in talks to buy Protagonist Therapeutics, WSJ reports

11:15 EDT J&J in talks to buy Protagonist Therapeutics (PTGX), WSJ reports Published first on TheFly – the...

2d ago

JNJ

PTGX

Protagonist Therapeutics jumps 9%, halted after WSJ report on J&J takeover talks

11:17 EDT Protagonist Therapeutics (PTGX) jumps 9%, halted after WSJ report on J&J takeover talks Published first on...

2d ago

JNJ

PTGX

Johnson & Johnson in talks to buy Protagonist Therapeutics, WSJ reports

Johnson & Johnson (JNJ) is in talks to buy Protagonist Therapeutics (PTGX), which had a market value of...

2d ago

JNJ

PTGX

Protagonist Therapeutics trading halted, volatility trading pause

11:13 EDT Protagonist Therapeutics (PTGX) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

2d ago

PTGX

Protagonist Therapeutics participates in a conference call with JPMorgan

Conference call with management will be held on October 10 at 2 pm hosted by JPMorgan.Webcast Link Published...

2d ago

PTGX

Protagonist Therapeutics price target raised to $74 from $62 at Clear Street

Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $74 from $62 and keeps a...

5d ago

JNJ

PTGX

Protagonist Therapeutics’ Icotrokinra: A Promising Blockbuster Candidate with Broad Therapeutic Potential

Analyst Yun Zhong from Wedbush maintained a Buy rating on Protagonist Therapeutics and keeping the price target at...

4d ago

PTGX

Protagonist Therapeutics’ Icotrokinra: Promising Phase 2b Results Reinforce Buy Rating

Analyst Evan Seigerman of BMO Capital reiterated a Buy rating on Protagonist Therapeutics, with a price target of...

4d ago

PTGX

PTGX FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?

Protagonist Therapeutics lowest stock price was $33.31 and its highest was $68.26 in the past 12 months.

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is $4.06B.

When is Protagonist Therapeutics’s upcoming earnings report date?

Protagonist Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 24 days.

How were Protagonist Therapeutics’s earnings last quarter?

Protagonist Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.579 by $0.029.

Is Protagonist Therapeutics overvalued?

According to Wall Street analysts Protagonist Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics does not currently pay dividends.

What is Protagonist Therapeutics’s EPS estimate?

Protagonist Therapeutics’s EPS estimate is -0.61.

How many shares outstanding does Protagonist Therapeutics have?

Protagonist Therapeutics has 62,211,320 shares outstanding.

What happened to Protagonist Therapeutics’s price movement after its last earnings report?

Protagonist Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.579. Following the earnings report the stock price went down -5.384%.

Which hedge fund is a major shareholder of Protagonist Therapeutics?

Currently, no hedge funds are holding shares in PTGX

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

8.61%

Trailing 12-Months

Asset Growth

16.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics

Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel peptide-based therapeutics for the treatment of various diseases, particularly hematologic malignancies and autoimmune disorders. The company leverages its proprietary technology platform to design and optimize peptide drugs that aim to address unmet medical needs in these therapeutic areas.

Protagonist Therapeutics (PTGX) Earnings & Revenues

Historic Earnings Reports

PTGX Stock 12 Month Forecast

Average Price Target

$73.09

▼(-15.99% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","83":"$83","47.75":"$47.8","59.5":"$59.5","71.25":"$71.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$73.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,47.75,59.5,71.25,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64,65.38461538461539,66.76923076923077,68.15384615384616,69.53846153846153,70.92307692307692,72.3076923076923,73.6923076923077,75.07692307692308,76.46153846153847,77.84615384615384,79.23076923076923,80.61538461538461,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64,64.69923076923077,65.39846153846153,66.09769230769231,66.79692307692308,67.49615384615385,68.19538461538461,68.89461538461539,69.59384615384616,70.29307692307692,70.99230769230769,71.69153846153847,72.39076923076924,{"y":73.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64,64.07692307692308,64.15384615384616,64.23076923076923,64.3076923076923,64.38461538461539,64.46153846153847,64.53846153846153,64.61538461538461,64.6923076923077,64.76923076923077,64.84615384615384,64.92307692307692,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >